investment & stocks ideas
Estrella Immunopharma, Inc. (ESLA) is a clinical-stage biopharmaceutical company developing novel antibody and cell-based therapies for the treatment of cancer and infectious diseases. The company's lead product candidate, EstreLA-1, is a humanized monoclonal antibody targeting the interleukin-2 receptor (IL-2R) that is being developed for the treatment of solid tumors and certain hematological malignancies. EstreLA-1 is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The company's other product candidates include EstreLA-2, a humanized monoclonal antibody targeting the tumor necrosis factor (TNF) receptor superfamily member 14 (TRAF14), which is being developed for the treatment of inflammatory diseases and certain types of cancer; and EstreLA-3, a chimeric antigen receptor (CAR) T-cell therapy targeting the B cell maturation antigen (BCMA), which is being developed for the treatment of multiple myeloma and other B-cell malignancies. |